Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222807 · ClinicalTrials.gov registry record
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 200
- Enrollment target
NCT00222807 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 200 participants.
The verdict
NCT00222807 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls. Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2003-08 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222807
The ClinicalTrials.gov registry entry for NCT00222807 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00222807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222807 about?
NCT00222807 is a clinical study titled "Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus". This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and ...
What is the current status of trial NCT00222807?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2003-08. Estimated completion is 2016-03.
Who is sponsoring clinical trial NCT00222807?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.